Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Macy's Inc (M) vs Revvity Inc (RVTY) Price & Performance

Macy's IncTrade
Revvity IncTrade

Price performance (Past 24H)

Key statistics

Macy's Inc vs Revvity Inc — how do they compare? Macy's Inc trades at $22.63 (market cap $5.95B), while Revvity Inc trades at $152.05 (market cap $16.98B). The key difference: Revvity Inc is far larger — about 2.9× Macy's Inc's market cap, and Macy's Inc pays the higher dividend (3.36%). Which is the better fit depends on your goals — on Pluang, investors hold Macy's Inc for 58 Days and Revvity Inc for 12 Days on average.

MRVTY
Market Cap
$5.95B$16.98B
Volume
6,030,6441,456,900
Sector
Consumer CyclicalHealth
52-Week High
$26.21$157.36
52-Week Low
$16.51$82.26
Typical Hold Time
58 Days12 Days
Enterprise Value
$9.75B$19.30B
Dividend Yield
3.36%0.18%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Macy's Inc

Macy's (M) trades at $22.79, up 1.47% today, with a bullish technical signal from moving averages. The stock shows attractive valuation with a P/E of 8.35 and P/S of 0.27. Recent earnings have consistently beaten estimates, and the company's 'Bold New Chapter' strategy is driving digital and omnichannel growth, though revenue has trended down from $25.3B in 2022 to $23.0B in 2025.

The outlook is mixed; strong cash flow and a 3.5% dividend yield support income investors, but competitive pressures and uneven growth pose risks. Analyst consensus is a $24.25 price target with a Hold bias. Execution of the turnaround strategy remains key to unlocking value amid retail sector challenges.

Revvity Inc

RVTY trades at $153.60, up 0.2% today and near its 52-week high of $158.28 (Defense World, 2026-10-01). The stock shows a bullish technical trend with strong moving average signals and has beaten earnings estimates for three consecutive quarters. Recent developments include the launch of a CE-IVDR-certified T1D screening kit in Europe (Business Wire, 2026-09-24) and the acquisition of Human Cell Design to expand metabolic disease research tools (Business Wire, 2026-09-09).

The outlook is positive, supported by earnings momentum, strategic acquisitions, and analyst optimism. However, the stock trades at a premium valuation with a P/E of 73.15, and near-term risks include margin pressures in China and rich valuation limiting upside beyond consensus targets. Revenue stability but slight profit margin compression in 2026 warrants monitoring.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

M
100% Buy0% Sell
Avg holding period · 58 Days
RVTY

No sentiment data available yet.

Top news

Latest headlines on both assets

About Macy's Inc

Founded in 1858 and based in New York City, Macy's operates 570 stores under the Macy's nameplate, 58 stores under the Bloomingdale's nameplate, and 160 freestanding Bluemercury specialty beauty stores (as of the end of fiscal-year 2021). Macy's also operates e-commerce sites and licenses two Bloomingdale's stores in the United Arab Emirates and Kuwait. Women's apparel, accessories, shoes, cosmetics, and fragrances comprised 59% of Macy's 2021 sales.

Read more on M →

About Revvity Inc

Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.

Read more on RVTY →